Header Logo

Connection

ALEXANDER LAZAR to Cell Line, Tumor

Back to Details
This is a "connection" page, showing publications ALEXANDER LAZAR has written about Cell Line, Tumor.
ALEXANDER LAZAR
Connection Strength
0.728
Cell Line, Tumor
  1. EWSR1 fusion proteins mediate PAX7 expression in Ewing sarcoma. Mod Pathol. 2017 09; 30(9):1312-1320.
    View in: PubMed
    Score: 0.049
  2. RNA interference of PARG could inhibit the metastatic potency of colon carcinoma cells via PI3-kinase/Akt pathway. Cell Physiol Biochem. 2012; 29(3-4):361-72.
    View in: PubMed
    Score: 0.034
  3. An iron-rich subset of macrophages promotes tumor growth through a Bach1-Ednrb axis. J Exp Med. 2024 Oct 07; 221(10).
    View in: PubMed
    Score: 0.020
  4. Ataxia-Telangiectasia Mutated Loss-of-Function Displays Variant and Tissue-Specific Differences across Tumor Types. Clin Cancer Res. 2024 May 15; 30(10):2121-2139.
    View in: PubMed
    Score: 0.020
  5. Microparticle-Delivered Cxcl9 Prolongs Braf Inhibitor Efficacy in Melanoma. Cancer Immunol Res. 2023 05 03; 11(5):558-569.
    View in: PubMed
    Score: 0.018
  6. Frequent TRPS1 expression in synovial sarcoma is associated with SS18-SSX fusion oncoprotein activity. Hum Pathol. 2022 Dec; 130:88-94.
    View in: PubMed
    Score: 0.018
  7. Comprehensive Surfaceome Profiling to Identify and Validate Novel Cell-Surface Targets in Osteosarcoma. Mol Cancer Ther. 2022 06 01; 21(6):903-913.
    View in: PubMed
    Score: 0.017
  8. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun. 2022 06 01; 13(1):3057.
    View in: PubMed
    Score: 0.017
  9. The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma. Mol Cell. 2022 05 05; 82(9):1737-1750.e8.
    View in: PubMed
    Score: 0.017
  10. The clear cell sarcoma functional genomic landscape. J Clin Invest. 2021 08 02; 131(15).
    View in: PubMed
    Score: 0.016
  11. Enhancer reprogramming in PRC2-deficient malignant peripheral nerve sheath tumors induces a targetable de-differentiated state. Acta Neuropathol. 2021 09; 142(3):565-590.
    View in: PubMed
    Score: 0.016
  12. Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy. Cell Rep. 2021 07 20; 36(3):109410.
    View in: PubMed
    Score: 0.016
  13. Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. Nat Med. 2021 08; 27(8):1432-1441.
    View in: PubMed
    Score: 0.016
  14. Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma. Cell Rep. 2021 01 26; 34(4):108678.
    View in: PubMed
    Score: 0.016
  15. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma. Cell Rep. 2020 10 20; 33(3):108293.
    View in: PubMed
    Score: 0.016
  16. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomater. 2019 12; 100:38-51.
    View in: PubMed
    Score: 0.014
  17. p53 Is a Master Regulator of Proteostasis in SMARCB1-Deficient Malignant Rhabdoid Tumors. Cancer Cell. 2019 02 11; 35(2):204-220.e9.
    View in: PubMed
    Score: 0.014
  18. T-cell trafficking plays an essential role in tumor immunity. Lab Invest. 2019 01; 99(1):85-92.
    View in: PubMed
    Score: 0.014
  19. The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma. Cancer Cell. 2018 06 11; 33(6):1128-1141.e7.
    View in: PubMed
    Score: 0.013
  20. Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas. Cell Rep. 2018 04 03; 23(1):194-212.e6.
    View in: PubMed
    Score: 0.013
  21. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers. Cell Rep. 2018 04 03; 23(1):227-238.e3.
    View in: PubMed
    Score: 0.013
  22. A Preexisting Rare PIK3CAE545K Subpopulation Confers Clinical Resistance to MEK plus CDK4/6 Inhibition in NRAS Melanoma and Is Dependent on S6K1 Signaling. Cancer Discov. 2018 05; 8(5):556-567.
    View in: PubMed
    Score: 0.013
  23. Co-targeting PI3K, mTOR, and IGF1R with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. 2017 10 03; 18(10):816-826.
    View in: PubMed
    Score: 0.013
  24. Targeting group I p21-activated kinases to control malignant peripheral nerve sheath tumor growth and metastasis. Oncogene. 2017 09 21; 36(38):5421-5431.
    View in: PubMed
    Score: 0.012
  25. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst. 2016 12; 108(12).
    View in: PubMed
    Score: 0.012
  26. Establishment and characterization of a new human myxoid liposarcoma cell line (DL-221) with the FUS-DDIT3 translocation. Lab Invest. 2016 08; 96(8):885-94.
    View in: PubMed
    Score: 0.011
  27. Poly (ADP) ribose polymerase inhibition: A potential treatment of malignant peripheral nerve sheath tumor. Cancer Biol Ther. 2016; 17(2):129-38.
    View in: PubMed
    Score: 0.011
  28. Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discov. 2016 Feb; 6(2):202-16.
    View in: PubMed
    Score: 0.011
  29. AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas. BMC Cancer. 2015 Nov 14; 15:901.
    View in: PubMed
    Score: 0.011
  30. The genomic landscape of epithelioid sarcoma cell lines and tumours. J Pathol. 2016 Jan; 238(1):63-73.
    View in: PubMed
    Score: 0.011
  31. SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma. Clin Cancer Res. 2016 Mar 01; 22(5):1150-60.
    View in: PubMed
    Score: 0.011
  32. Increased H3K9me3 drives dedifferentiated phenotype via KLF6 repression in liposarcoma. J Clin Invest. 2015 Aug 03; 125(8):2965-78.
    View in: PubMed
    Score: 0.011
  33. The hepatocyte growth factor receptor as a potential therapeutic target for dedifferentiated liposarcoma. Lab Invest. 2015 Aug; 95(8):951-61.
    View in: PubMed
    Score: 0.011
  34. Antitumor effects of pharmacological EZH2 inhibition on malignant peripheral nerve sheath tumor through the miR-30a and KPNB1 pathway. Mol Cancer. 2015 Mar 07; 14:55.
    View in: PubMed
    Score: 0.011
  35. NKD2, a negative regulator of Wnt signaling, suppresses tumor growth and metastasis in osteosarcoma. Oncogene. 2015 Sep 24; 34(39):5069-79.
    View in: PubMed
    Score: 0.010
  36. Gankyrin is a predictive and oncogenic factor in well-differentiated and dedifferentiated liposarcoma. Oncotarget. 2014 Oct 15; 5(19):9065-78.
    View in: PubMed
    Score: 0.010
  37. Gauging NOTCH1 Activation in Cancer Using Immunohistochemistry. PLoS One. 2013; 8(6):e67306.
    View in: PubMed
    Score: 0.009
  38. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc Natl Acad Sci U S A. 2013 Apr 16; 110(16):6500-5.
    View in: PubMed
    Score: 0.009
  39. Telomerase suppresses formation of ALT-associated single-stranded telomeric C-circles. Mol Cancer Res. 2013 Jun; 11(6):557-67.
    View in: PubMed
    Score: 0.009
  40. Targeting the PI3K/mTOR axis, alone and in combination with autophagy blockade, for the treatment of malignant peripheral nerve sheath tumors. Mol Cancer Ther. 2012 Aug; 11(8):1758-69.
    View in: PubMed
    Score: 0.009
  41. Dual targeting of mTOR and aurora-A kinase for the treatment of uterine Leiomyosarcoma. Clin Cancer Res. 2012 Sep 01; 18(17):4633-45.
    View in: PubMed
    Score: 0.009
  42. MiR-155 is a liposarcoma oncogene that targets casein kinase-1a and enhances ?-catenin signaling. Cancer Res. 2012 Apr 01; 72(7):1751-62.
    View in: PubMed
    Score: 0.009
  43. ROR2 is a novel prognostic biomarker and a potential therapeutic target in leiomyosarcoma and gastrointestinal stromal tumour. J Pathol. 2012 Jun; 227(2):223-33.
    View in: PubMed
    Score: 0.009
  44. Combining EGFR and mTOR blockade for the treatment of epithelioid sarcoma. Clin Cancer Res. 2011 Sep 15; 17(18):5901-12.
    View in: PubMed
    Score: 0.008
  45. Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors. Clin Cancer Res. 2011 Jun 15; 17(12):3943-55.
    View in: PubMed
    Score: 0.008
  46. Epithelioid sarcoma and unclassified sarcoma with epithelioid features: clinicopathological variables, molecular markers, and a new experimental model. Oncologist. 2011; 16(4):512-22.
    View in: PubMed
    Score: 0.008
  47. Autophagic survival in resistance to histone deacetylase inhibitors: novel strategies to treat malignant peripheral nerve sheath tumors. Cancer Res. 2011 Jan 01; 71(1):185-96.
    View in: PubMed
    Score: 0.008
  48. An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors. Lab Invest. 2011 Mar; 91(3):392-403.
    View in: PubMed
    Score: 0.008
  49. Vimentin is a novel AKT1 target mediating motility and invasion. Oncogene. 2011 Jan 27; 30(4):457-70.
    View in: PubMed
    Score: 0.008
  50. TRAIL and doxorubicin combination induces proapoptotic and antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res. 2010 May 01; 16(9):2591-604.
    View in: PubMed
    Score: 0.007
  51. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates. Mol Cancer Ther. 2009 Aug; 8(8):2079-85.
    View in: PubMed
    Score: 0.007
  52. Dual targeting of AKT and mammalian target of rapamycin: a potential therapeutic approach for malignant peripheral nerve sheath tumor. Mol Cancer Ther. 2009 May; 8(5):1157-68.
    View in: PubMed
    Score: 0.007
  53. Increased vascular endothelial growth factor-C expression is insufficient to induce lymphatic metastasis in human soft-tissue sarcomas. Clin Cancer Res. 2009 Apr 15; 15(8):2637-46.
    View in: PubMed
    Score: 0.007
  54. IFN regulatory factor 8 sensitizes soft tissue sarcoma cells to death receptor-initiated apoptosis via repression of FLICE-like protein expression. Cancer Res. 2009 Feb 01; 69(3):1080-8.
    View in: PubMed
    Score: 0.007
  55. A novel AKT3 mutation in melanoma tumours and cell lines. Br J Cancer. 2008 Oct 21; 99(8):1265-8.
    View in: PubMed
    Score: 0.007
  56. Epidermal growth factor receptor blockade in combination with conventional chemotherapy inhibits soft tissue sarcoma cell growth in vitro and in vivo. Clin Cancer Res. 2008 May 01; 14(9):2785-95.
    View in: PubMed
    Score: 0.007
  57. Rad51 overexpression contributes to chemoresistance in human soft tissue sarcoma cells: a role for p53/activator protein 2 transcriptional regulation. Mol Cancer Ther. 2007 May; 6(5):1650-60.
    View in: PubMed
    Score: 0.006
  58. Wild-type p53 inhibits nuclear factor-kappaB-induced matrix metalloproteinase-9 promoter activation: implications for soft tissue sarcoma growth and metastasis. Mol Cancer Res. 2006 Nov; 4(11):803-10.
    View in: PubMed
    Score: 0.006
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.